Skip to main content

Table 1 Sociodemographic and clinical characteristics and duration of follow-up for Medicare-eligible stage IV ER + breast cancer patients who did not receive HER2 targeted agents and matched comparison patients

From: Survival, healthcare resource use and costs among stage IV ER + breast cancer patients not receiving HER2 targeted therapy: a retrospective analysis of linked SEER-Medicare data

Characteristic Study cohort Comparison cohort P-value***
N 325 325  
Age (years)*    
  Mean ± SD 77.18 ± 7.19 77.26 ± 7.75 0.813
  Median 77.00 76.00  
Race (%)*    1.000
  White 85.5% 85.5%  
  Black 10.2% 10.2%  
  Hispanic 0.6% 0.6%  
  Asian 2.2% 2.2%  
  Other 1.5% 1.5%  
Urban (%) 99.1% 96.6% 0.055
Geographic region (%)    0.005
  Northeast 30.8% 19.1%  
  Midwest 13.8% 12.9%  
  West 34.8% 42.5%  
  South 20.6% 25.2%  
Duration of follow-up (months)    
  Mean ± SD 18.12 ± 11.91 25.82 ± 8.94 < 0.001
  Median 20.00 28.00  
Charlson score**    
  Mean ± SD 1.12 ± 1.58 1.31 ± 1.71 0.072
  Median 1.00 1.00  
Charlson comorbidities (%)    
  Diabetes without chronic complications 25.8% 26.5% 0.929
  Chronic pulmonary disease 23.1% 20.3% 0.447
  Congestive heart failure 14.2% 12.0% 0.485
  Cerebrovascular disease 10.8% 16.3% 0.051
  Diabetes with chronic complications 7.7% 8.0% 1.000
  Renal disease 6.2% 7.1% 0.753
  Peripheral vascular disease 5.8% 8.9% 0.177
  Rheumatologic disease 4.3% 5.2% 0.713
  Myocardial infarction 3.7% 4.3% 0.842
  Dementia 2.2% 8.3% < 0.001
  Peptic ulcer disease 0.9% 2.2% 0.340
  Hemiplegia or paraplegia 0.3% 1.8% 0.123
  Moderate or severe liver disease 0.3% 0.3% 1.000
  AIDS 0.0% 0.0% < 0.001
  Mild liver disease 0.0% 0.6% 0.499
Other comorbidities (%)    
  Depression/anxiety 9.2% 17.8% 0.002
  Osteoporosis/Fractures 14.5% 25.8% < 0.001
PR status    
  PR+ 78.0% n/a  
  PR- 22.0% n/a  
  1. *Matching criteria.
  2. **Charlson score excludes any primary malignancy and metastatic solid tumor.
  3. ***Proportions were compared using the Fisher's exact test while continuous measures were compared using the nonparametric Wilcoxon test.